ConductScience.org, home

Paper21865415

Benign multiple sclerosis: a new definition of this entity is needed.

Correale J and 2 others. Mult Scler, 2012. Cited by 38 papers, by iCite.

Cite this record

ConductScience Library. Benign multiple sclerosis: a new definition of this entity is needed. Papers, record 21865415. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21865415

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Benign multiple sclerosis: a new definition of this entity is needed.
PubMed
Journal
Mult Scler
PubMed
Year
2012
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
38
iCite
Relative citation ratio, by iCite
1.4
iCite
Revised in PubMed
2012-02-07
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Correale JJorge
2Peirano IIsabel
3Romano LLucas

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Disability EvaluationMajor topic
Multiple SclerosisMajor topic
Severity of Illness IndexMajor topic
Adult
Cognition Disorders
Depression
Fatigue
Female
Follow-Up Studies
Humans
Incidence
Magnetic Resonance Imaging
Male
Neuropsychological Tests
Pain
Prognosis
Prospective Studies
Quality of Life

Source PubMed

Download CSV of topics

Cited by19

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 38 citations.

PMIDTitleJournalYearIn PapersSource
41191123Benign multiple sclerosis and long-term outcomes after 30 years.J Neurol2025https://conductscience.org/library/papers/41191123PubMed
39494361Early regional cerebral grey matter damage predicts long-term cognitive impairment phenotypes in multiple sclerosis: a 20-year study.Brain Commun2024https://conductscience.org/library/papers/39494361PubMed
38488979Holistic, Long-Term Management of People with Relapsing Multiple Sclerosis with Cladribine Tablets: Expert Opinion from France.Neurol Ther2024https://conductscience.org/library/papers/38488979PubMed
38420491Predictive factors and treatment challenges in malignant progression of relapsing-remitting multiple sclerosis.Heliyon2024https://conductscience.org/library/papers/38420491PubMed
35680693Symptom Interconnectivity in Multiple Sclerosis: A Narrative Review of Potential Underlying Biological Disease Processes.Neurol Ther2022https://conductscience.org/library/papers/35680693PubMed
35598225
Patterns of Utilization and Expenditure Across Multiple Sclerosis Disease-Modifying Therapies: A Retrospective Cohort Study Using Claims Data from a Commercially Insured Population in the United States, 2010-2019.
Neurol Ther2022https://conductscience.org/library/papers/35598225PubMed
33791847Long-term analysis of patients with benign multiple sclerosis: new insights about the disability course.J Neurol2021https://conductscience.org/library/papers/33791847PubMed
32763899Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis.AJNR Am J Neuroradiol2020https://conductscience.org/library/papers/32763899PubMed
31556809Cytokine-chemokine and cognitive profile of multiple sclerosis patients with predominant optic nerve and spinal cord involvement.J Spinal Cord Med2021https://conductscience.org/library/papers/31556809PubMed
30884218Impairment and restrictions in possibly benign multiple sclerosis.Brain Behav2019https://conductscience.org/library/papers/30884218PubMed
30742302Spatial distribution of white matter degenerative lesions and cognitive dysfunction in relapsing-remitting multiple sclerosis patients.Neurol Neurochir Pol2019https://conductscience.org/library/papers/30742302PubMed
30303036Recommendations for cognitive screening and management in multiple sclerosis care.Mult Scler2018https://conductscience.org/library/papers/30303036PubMed
28966652Optical coherence tomography and T cell gene expression analysis in patients with benign multiple sclerosis.Neural Regen Res2017https://conductscience.org/library/papers/28966652PubMed
27416843Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC).BMC Neurol2016https://conductscience.org/library/papers/27416843PubMed
25899600Decision-making under explicit risk is impaired in multiple sclerosis: relationships with ventricular width and disease disability.BMC Neurol2015https://conductscience.org/library/papers/25899600PubMed
24041438Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration.Eur J Radiol2013https://conductscience.org/library/papers/24041438PubMed
23643443Tract-specific white matter correlates of fatigue and cognitive impairment in benign multiple sclerosis.J Neurol Sci2013https://conductscience.org/library/papers/23643443PubMed
23473637Multiple sclerosis: molecular mechanisms and therapeutic opportunities.Antioxid Redox Signal2013https://conductscience.org/library/papers/23473637PubMed
22777531Benign multiple sclerosis: does it exist?Curr Neurol Neurosci Rep2012https://conductscience.org/library/papers/22777531PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/21865415

GET https://conductscience.org/api/papers/v1/21865415/authors